» Articles » PMID: 25688736

Cytokine Profile and Prognostic Significance of High Neutrophil-lymphocyte Ratio in Colorectal Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 2015 Feb 18
PMID 25688736
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High circulating neutrophil-lymphocyte ratio (NLR) appears to be prognostic in metastatic colorectal cancer (mCRC). We investigated the relationship of NLR with circulating cytokines and molecular alterations.

Methods: We performed retrospective analyses on multiple cohorts of CRC patients (metastatic untreated (n=166), refractory metastatic (n=161), hepatectomy (n=198), stage 2/3 (n=274), and molecularly screened (n=342)). High NLR (ratio of absolute neutrophil-to-lymphocyte counts in peripheral blood) was defined as NLR>5. Plasma cytokines were evaluated using multiplex-bead assays. Kaplan-Meier estimates, non-parametric correlation analysis, and hierarchical cluster analyses were used.

Results: High NLR was associated with poor prognosis in mCRC (hazard ratio (HR) 1.73; 95% confidence interval (CI):1.03-2.89; P=0.039) independent of known prognostic factors and molecular alterations (KRAS/NRAS/BRAF/PIK3CA/CIMP). High NLR correlated with increased expression of interleukin 6 (IL-6), IL-8, IL-2Rα, hepatocyte growth factor, macrophage-colony stimulating factor, and vascular epidermal growth factor in exploratory (n=39) and validation (n=166) cohorts. Fourteen additional cytokines correlated with high NLR in the validation cohort. All 20 cytokines fell into three major clusters: inflammatory cytokines, angiogenic cytokines, and epidermal growth factor ligands. In mCRC, composite stratification based on NLR-cytokine score provided enhanced prognostic information (HR 2.09; 95% CI: 1.59-2.76; P<0.001) over and above NLR.

Conclusions: High NLR is an independent poor prognostic marker in CRC and correlates with a distinct cytokine profile related to key biological processes involved in carcinogenesis. A composite NLR-cytokine stratification has enhanced prognostic value in mCRC.

Citing Articles

Optimal cutpoint of preoperative neutrophil-lymphocyte ratio and associated postoperative prognosis in colorectal cancer patients.

Chiu T, Liu T, Chang C, Hu W Int J Colorectal Dis. 2025; 40(1):55.

PMID: 40009243 PMC: 11865130. DOI: 10.1007/s00384-025-04839-4.


Diagnostic value of preoperative systemic inflammatory markers and carcinoembryonic antigen in medullary thyroid carcinoma and the risk factors affecting its prognosis.

Wu Z, Jiang Y, Gong H, Jiang T, Su A, Yi L Gland Surg. 2025; 14(1):13-27.

PMID: 39958900 PMC: 11826260. DOI: 10.21037/gs-24-397.


Hodgkin lymphoma and liquid biopsy: a story to be told.

Velasco-Suelto J, Galvez-Carvajal L, Comino-Mendez I, Rueda-Dominguez A J Exp Clin Cancer Res. 2024; 43(1):184.

PMID: 38956619 PMC: 11218217. DOI: 10.1186/s13046-024-03108-6.


Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

Ding Y, Liu Z, Li J, Niu W, Li C, Yu B BMC Surg. 2024; 24(1):89.

PMID: 38481180 PMC: 10935841. DOI: 10.1186/s12893-024-02384-5.


Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer.

Wang Q, Zhong W, Shen X, Hao Z, Wan M, Yang X NPJ Precis Oncol. 2024; 8(1):61.

PMID: 38431733 PMC: 10908779. DOI: 10.1038/s41698-024-00533-w.


References
1.
Proctor M, Horgan P, Talwar D, Fletcher C, Morrison D, McMillan D . Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer. 2013; 119(12):2325-32. DOI: 10.1002/cncr.28018. View

2.
Coussens L, Zitvogel L, Palucka A . Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science. 2013; 339(6117):286-91. PMC: 3591506. DOI: 10.1126/science.1232227. View

3.
Proctor M, McMillan D, Morrison D, Fletcher C, Horgan P, Clarke S . A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012; 107(4):695-9. PMC: 3419948. DOI: 10.1038/bjc.2012.292. View

4.
Jurgensmeier J, Schmoll H, ROBERTSON J, Brooks L, Taboada M, Morgan S . Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013; 108(6):1316-23. PMC: 3619270. DOI: 10.1038/bjc.2013.79. View

5.
Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View